Zenas BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	1	10	5	50	-
Revenue Growth	-93.33%	100.00%	-90.00%	-	-
Cost of Revenue	213.47	168.06	139.14	60.03	61.69
Gross Profit	-212.47	-158.06	-134.14	-10.03	-61.69
Selling, General & Admin	61.43	53.32	29.75	17.11	13.51
Operating Expenses	61.43	53.32	29.75	17.11	13.51
Operating Income	-273.9	-211.39	-163.89	-27.15	-75.2
Interest Expense	-24.26	-7.33	-	-	-
Interest & Investment Income	15.64	12.15	7.97	-	-
Currency Exchange Gain (Loss)	0.3	0.3	-	0.1	-
Other Non Operating Income (Expenses)	-0.27	0.12	0.2	0.52	-43.08
EBT Excluding Unusual Items	-282.49	-206.14	-155.71	-26.52	-118.28
Other Unusual Items	-	-	-0.85	-0.3	-
Pretax Income	-484.16	-377.82	-156.56	-36.82	-119.28
Income Tax Expense	0.22	-0.08	0.43	0.3	-
Net Income	-484.38	-377.74	-156.99	-37.12	-119.28
Net Income to Common	-484.38	-377.74	-156.99	-37.12	-119.28
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	54	45	13	2	1
Shares Outstanding (Diluted)	54	45	13	2	1
Shares Change	60.52%	238.89%	762.01%	2.61%	-
EPS (Basic)	-9.05	-8.44	-11.89	-24.25	-79.94
EPS (Diluted)	-9.05	-8.44	-11.89	-24.25	-79.94
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-225.97	-172.35	-119.81	-30.55	-65.85
Free Cash Flow Per Share	-4.22	-3.85	-9.08	-19.95	-44.13
Gross Margin	-	-	-	-20.07%	-
Operating Margin	-27390.10%	-2113.85%	-3277.76%	-54.29%	-
Profit Margin	-48438.40%	-3777.37%	-3139.76%	-74.25%	-
Free Cash Flow Margin	-22597.40%	-1723.51%	-2396.10%	-61.09%	-
EBITDA	-273.87	-211.33	-163.75	-27.03	-75.12
EBITDA Margin	-	-	-	-54.07%	-
D&A For EBITDA	0.03	0.06	0.14	0.11	0.08
EBIT	-273.9	-211.39	-163.89	-27.15	-75.2
EBIT Margin	-	-	-	-54.29%	-
Revenue as Reported	1	10	5	50	-

SEC Filings: 10-K · 10-Q